New Triple-Threat drug combo targets deadly brain tumors from skin cancer
NCT ID NCT06712927
Summary
This study is testing a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) in people whose melanoma skin cancer has spread to their brain. The main goal is to see if this treatment can shrink or control the brain tumors for at least six months. It will also check how well the drugs work on cancer in the rest of the body and monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.